GlassScriptPhysician profile
Marissa Dorau
NPI 1114279965
$697.70
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.75 · 2022: $176 · 2023: $17.03 · 2024: $160 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $138.31 | 2022-2023 | Bexsero |
| Kowa Pharmaceuticals America, INC. | $136.82 | 2025 | Zoryve |
| Abbvie INC. | $90.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $73.27 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Kaleo, INC. | $61.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.88 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $28.54 | 2024-2025 | Airsupra, Farxiga |
| Phadia US INC. | $24.13 | 2024 | Immunocap |
| Lilly USA, LLC | $18.77 | 2024 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $17.66 | 2025 | Xyosted |
| Bausch Health US, LLC | $17.46 | 2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $13.94 | 2025 | Jornay Pm |
| Amgen INC. | $13.87 | 2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2024 | Jardiance |
| Novo Nordisk INC | $13.52 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Dorau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.